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Abstract
Background: The objectives of this study were to evaluate long-term results of concurrent
chemoradiotherapy (CRT) with 5-fluorouracil and cisplatin and the potential benefit of
consolidation chemotherapy in patients with anal squamous cell carcinoma (ASCC).
Methods: Between January 1995 and February 2006, 31 patients with ASCC were treated with
CRT. Radiotherapy was administered at 45 Gy over 5 weeks, followed by a boost of 9 Gy to
complete or partial responders. Chemotherapy consisted of 5-fluorouracil (750 or 1,000 mg/m2)
daily on days 1 to 5 and days 29 to 33; and, cisplatin (75 or 100 mg/m2) on day 2 and day 30. Twelve
patients had T3–4 disease, whereas 18 patients presented with lymphadenopathy. Twenty-one
(67.7%) received consolidation chemotherapy with the same doses of 5-fluorouracil and cisplatin,
repeated every 4 weeks for maximum 4 cycles.
Results: Nineteen patients (90.5%) completed all four courses of consolidation chemotherapy.
After CRT, 28 patients showed complete responses, while 3 showed partial responses. After a
median follow-up period of 72 months, the 5-year overall, disease-free, and colostomy-free survival
rates were 84.7%, 82.9% and 96.6%, demonstrating that CRT with 5-fluorouracil and cisplatin yields
a good outcome in terms of survival and sphincter preservation. No differences in 5-year OS and
DFS rates between patients treated with CRT alone and CRT with consolidation chemotherapy
was observed.
Conclusion: our study shows that CRT with 5-FU and cisplatin, with or without consolidation
chemotherapy, was well tolerated and proved highly encouraging in terms of long-term survival and
the preservation of anal function in ASCC. Further trials with a larger patient population are
warranted in order to evaluate the potential role of consolidation chemotherapy.
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Previous to work by Nigro et al. in 1974 which pioneered
a concurrent chemoradiotherapy (CRT), the treatment of
choice for anal squamous cell carcinoma (ASCC) was sur-
gical resection [1]. Since then, combination chemother-
apy and radiotherapy has been explored, and has led to
local control rates of 60–90% and 5-year survival rates of
60–90% without the need for colostomy [2-4]. Thus, sur-
gical resection is no longer considered a necessary treat-
ment and has been reserved for only persistent or
progressive disease.
Although increasing evidence indicates that combined
modality therapy yields high local control and spares the
anal sphincter, the optimal chemotherapy regimen has
not been determined [5-10]. CRT with 5-fluorouracil (5-
FU) and mitomicin-C (MMC) has also been evaluated in
several randomized trials which demonstrated significant
reductions in local failures, recurrence and subsequent
colostomy [11-13]. In a study led by The United Kingdom
Coordinating Committee on Cancer Research (UKCCCR),
patients were randomized to either radiation to 45 Gy
over 4–5 weeks or same radiation dose in combination
with 5-FU and MMC [11]. Local failure rate was signifi-
cantly lower in CRT arm than in the radiation alone arm.
There was not, however, a statistically significant differ-
ence in overall survival. The second randomized phase III
trial, conducted by the European Organization for
Research and Treatment of Cancer (EORTC) Radiotherapy
and Gastrointestinal Cooperative Groups, reported higher
complete response rate, locoregional control rate, and
colostomy-free survival rate with the addition of chemo-
therapy [12]. Furthermore, Intergroup trial (RTOG 87-04/
ECOG1289) clearly demonstrated beneficial effects of
MMC in combination regimen [13]. These studies
strongly support CRT with 5-FU and MMC as the standard
care for treatment of ASCC. Nevertheless, a significant
proportion of patients continued to experience treatment
failure and significant morbidity. In the Intergroup trial
(RTOG 87-04/ECOG1289), 18% of patients experienced
local-regional failure after 4 years despite treatment with a
combined modality therapy [13]. Among 146 evaluable
patients randomized to radiation, 5-FU, and MMC, 26%
had life-threatening or lethal toxicity, including 4 fatali-
ties. Concern regarding combination chemotherapy
focused particularly on MMC, which can cause severe, life-
threatening hematologic toxicity, lung toxicity, and
hemolytic-uremic syndrome. Thus, there exists a need to
consider alternatives to this regimen that can offer a more
favorable therapeutic ratio.
Several studies suggest that cisplatin might be an effective
substitute for MMC in ASCC [3,4,14-19]. A high response
rate was reported in patients with locally recurrent or met-
astatic anal cancer treated with 5-FU and cisplatin [18].
However, reports of CRT using cisplatin-based chemo-
therapy remain scarce.
Consolidation chemotherapy is the prolongation of
chemotherapy duration with the administration of addi-
tional drugs at the end of a defined number of initial
chemotherapy cycles, after achieving a maximum tumor
response in an individual patient [20]. In the absence of
significant toxicity, consolidation chemotherapy is con-
tinued either for a defined time or until evidence of pro-
gressive disease. The rationale for consolidation
chemotherapy is provided both by the Goldie and Cold-
man hypothesis [21], stating that the early use of non-
cross-resistant agents might increase the probability of
killing more cancer cells before resistance arises, and by
the Day model [22], indicating that the most active regi-
mens should be used as a consolidation treatment to opti-
mize results. Recently, the usage of consolidation
chemotherapy has demonstrated a potential for improv-
ing progression-free and overall survival in small cell lung
cancer [23], non-small cell lung cancer [24,25], and ovar-
ian cancer [26].
The objectives of this study were (1) to evaluate long-term
results using CRT with 5-FU and cisplatin, and (2) to ana-
lyze the potential of consolidation chemotherapy for
improving the outcome of patients with ASCC.
Methods
Patients eligibility
Between January 1995 and February 2006, a series of 31
patients presenting with ASCC were treated with CRT with
5-FU and cisplatin. Twenty-one (67.7%) of all patients
received consolidation chemotherapy with the same
doses of 5-FU and cisplatin, repeated every 4 weeks for
maximum 4 cycles. Medical records of all patients were
reviewed retrospectively.
Initial clinical work-up was performed with a careful dig-
ital examination of the anus, rectal wall, recto-vaginal sep-
tum and anoscopy or proctoscopy. All patients underwent
biopsy of an anal mass or ulcer prior to referral for chem-
otherapy and radiotherapy. Any suspicious inguinal
lymph nodes were biopsied, and pelvic CT scans and chest
X-rays were performed in all patients. The staging of the
tumors was done according to the UICC criteria of 2002.27
The institutional review board of the hospital approved
this protocol, and written informed consent was obtained
from all patients.
Treatment plan
Chemotherapy was given during the first course of radio-
therapy and consisted of (1) 5-FU (1,000 mg/m2 per day)
on days 1 to 5, repeated on days 29 to 33 by 120-h contin-
uous infusion (reduced to 750 mg/m2 in 10 patients inPage 2 of 8
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by responding physicians), and (2) cisplatin (100 mg/m2)
on days 2 and 30 (reduced to 75 mg/m2 in 15 patients).
Consolidation chemotherapy consisted of same regimen,
repeated every 4 weeks for maximum 4 cycles. Patients
were required to have an absolute neutrophil count
(ANC) ≥ 1,500/µl without evidence of active infection,
platelet count ≥ 100,000/µl, and resolution of any nonhe-
matologic toxicity to less than grade 2 before receiving
subsequent cycles of chemotherapy. A dose reduction of
5-FU and/or cisplatin to 10% was prescribed in cases of
bone marrow suppression (absolute neutrophil count <
1000/µL and platelet count < 75,000/µL), febrile neutro-
penia and grade 3 or more chemotherapy-related non-
hematologic toxicity. Antiemetic therapy was given rou-
tinely before the chemotherapy. Granulocyte-colony stim-
ulating factor (G-CSF) was not planned as a prophylactic
aim.
External beam radiotherapy consisted of 45 grays (Gy) in
25 fractions to the pelvis, perineum, and both inguinal
lymph nodes. All patients were treated with anterior and
posterior fields for the initial 45 Gy at 1.8 Gy per fraction,
five times per week. The superior border was located at the
bottom of the sacroiliac joints, the inferior border was at
least 3 cm below the most inferior portion of the tumor or
anal verge, and lateral borders covered the medial
inguinal lymph nodes. A boost of 9 Gy was given to com-
plete or partial responders.
Evaluation of results
Tumor response was assessed by clinical examination, sig-
moidoscopy, often with full-thickness biopsy, and pelvic
CT scan 4 to 6 weeks following the completion of chemo-
radiotherapy. Response was evaluated according to WHO
criteria. Complete response (CR) was defined as the com-
plete disappearance of all measurable disease for a dura-
tion of at least 4 weeks, and partial response (PR) as a
greater than 50% reduction of all measurable tumor sites.
Stable disease (SD) was defined as a less than 50% reduc-
tion of tumor lesions and no progression of more than
25% in tumor diameter. The responses of initially meta-
static lymph nodes were gauged by palpation by the
attending physician. If palpation proved equivocal, the
physician used a fine-needle biopsy at his/her discretion.
In patients who showed PR at first tumor response,
response evaluation was repeated with clinical examina-
tion and pelvic CT every 2 months during consolidation
chemotherapy.
Patients were seen weekly during chemoradiotherapy,
biweekly during consolidation chemotherapy, and there-
after every 3–6 months throughout the follow-up. Chest
X-ray and pelvic CT were performed annually. Toxicities
were graded according to the Common Toxicity Criteria of
the National Cancer Institute, version 1.0 or 2.0 [27].
Statistical Analysis
Local recurrence was defined as tumor recurrence in the
anus. Inguinal and/or pelvic lymph nodes within the irra-
diated volume were also scored as local recurrence. Other
sites of recurrence were scored as distant metastases. Com-
parison of recurrence patterns was made using a Fisher's
Exact test. Disease-free survival (DFS) was defined from
the date of negative biopsy to recurrence of cancer or
death of any cause. Overall survival (OS) was defined
from the date of diagnosis to the date of death by any
cause. Colostomy-free survival (CFS) was defined as inter-
val between the date of diagnosis and the first colostomy.
Survival curves were estimated using the Kaplan-Meier
method and the differences in survival between the
groups were assessed by a log-rank test.
Meticulous follow-up was done to confirm that deceased
patients who had been marked as having no evidence of




Pretreatment characteristics of patients and tumors are
summarized in Table 1. The median age of all patients was
57 years (range, 29–75). There were a total of 11 male and
20 female patients. The histology of all primary tumors
was identified as squamous cell carcinoma arising in the
anal canal. The T stages of 31 primary tumors, using AJCC
criteria [28], were: two T1, seventeen T2, seven T3, and
five T4 lesions. Twelve patients (38.7%) presented with
synchronous inguinal node metastases, as verified by his-
tology. Six patients with palpable perirectal nodes were
presumed positive for tumor and not biopsied due to
technical difficulties. About half of the patients presented
with advanced cases, with 18 patients (58.1%) having
tumors of 4 cm or more in maximal diameter and only 6
patients (19.4%) with tumors smaller than 4 cm without
any metastatic nodes. Twenty-one (67.7%) of all patients
received at least one cycle of consolidation chemotherapy.
Treatment compliance
The median actual dose of radiation administered was 54
Gy (range, 41.4– 64.8 Gy). The anticipated duration of
treatment was 42 days, whereas the actual duration was a
median of 45 days (range, 31–67 days). The treatment
lasted longer than 49 days in 9 patients (29%). Thus, 71%
of the patients finished treatment within 7 days of the
planned duration date. The primary cause of schedule
delays was related to radiation dermatitis. The patient,
who received a total of 64.8 Gy, had initially diagnosed as
stage T4N2 and still had grossly residual tumor after CRT.Page 3 of 8
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boost of 19.8 Gy to this patient.
Ten patients received 750 mg/m2 of 5-FU and 15 patients
did 75 mg/m2 of cisplatin instead of the initial planned
dose (1,000 mg/m2 of 5-FU and 100 mg/m2 of cisplatin,
respectively) due to advanced age (median 61 years) or
poor performance status, which precluded full-dose
administrations. There were 7 cases (29%) of chemother-
apy delay or dose reduction due to hematologic toxicities
or grade 3 urinary tract infection during chemoradiother-
apy. One patient refused further chemotherapy after com-
pletion of the first cycle. Based on the initial planned dose
(standard), the median actual dose intensities of 5-FU and
cisplatin, administered concurrently with radiation, were
1428.6 mg/m2/week (range, 625.0–1666.7) and 26.7 mg/
m2/week (range, 16.7–33.3), respectively. Median relative
dose intensities (RDI) of both 5-FU and cisplatin were
0.86 (range, 0.37–1.0) and 0.80 (range, 0.50–1.0), respec-
tively.
Twenty-one (67.7%) of all patients were treated with con-
solidation chemotherapy. The remaining 10 patients
could not undergo chemotherapy due to poor perform-
ance status following CRT (3 patients), toxicities during
CRT (2 patients with radiation dermatitis) or patients'
refusal (5 patients). Of the 21 patients who started consol-
idation chemotherapy, 2 failed to complete all four cycles
due to aggravating underlying renal insufficiency and
patient's refusal, respectively. Therefore, a total of 79
cycles of consolidation chemotherapy were administered
with a median of 4 cycles (range, 1–4). In this group, the
median RDI of both 5-FU and cisplatin were 0.89 (range,
0.38–1.0) and 0.82 (range, 0.28–1.0), respectively. There
were 8 cases (38.1%) of chemotherapy delay or dose
reduction during consolidation chemotherapy. The
causes of dose reduction or schedule delay were hemato-
logic toxicity (7 patients) and asthenia (1 patient), respec-
tively.
Overall, patient compliance was 96.8% for the CRT and
90.5% for the consolidation chemotherapy.
Tumor response to treatments
Primary tumor responses were assessed by full-thickness
biopsy in all cases. After CRT, 28 (90.3%) patients showed
CR, while 3 (9.7%) showed PR. Three patients with resid-
ual disease received consolidation chemotherapy with the
same regimen instead of APR. Two out of these 3 patients
achieved CR after completion of consolidation chemo-
therapy and remained disease-free at 1 and 2 years, respec-
tively. One patient still had metastatic disease in the
inguinal lymph node as well as a residual lesion in the
anal canal following consolidation chemotherapy. This
patient received re-irradiation as salvage treatment, and
died of progressive disease.
Disease-free, colostomy-free, and overall survival
At a median follow-up of 72 months (range, 14–137
months), 5 recurrences and 8 deaths were recorded. Over-
all, 2 patients presented with a locoregional recurrence (1
in the anal canal and 1 in the inguinal lymph node). One
of these patients had previously received CRT alone, while
the other patient underwent 4 additional cycles of consol-
idation chemotherapy. The time from the end of treat-
ment to recurrence was 12 months and 6 months for the
two patients, respectively. One patient received abdomi-
noperineal resection (APR) as a salvage therapy. However,
this patient subsequently developed distant metastases
and died of it. The other patient refused further treatment
and is still alive after 30 months.
The two patients, who were previously treated with CRT
alone and 4 cycles of consolidation chemotherapy,
respectively, developed distant metastases. One had
simultaneous metastases to the lung and liver 64 months
after the end of treatment, and the other presented with
multiple lymph node metastasis 24 months after the end
of treatment. Finally, one patient who was treated with
CRT alone had simultaneous local and distant metastatic
Table 1: Patient characteristics.
Characteristics Total n = 31
























Consolidation chemotherapy 4 (12.9)
Yes 21 (67.7)
No 10 (32.3)Page 4 of 8
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received platinum-based chemotherapies as salvage thera-
pies, but died of progressive disease. The local control rate
at 5 years was 87.1%. The distant control rate at 5 years
was 90.3%. When we compared the recurrence pattern of
patients treated with CRT alone to those treated with CRT
with consolidation chemotherapy, no significant differ-
ence was found.
Five of 8 deaths were due to anal cancer. Three patients
died of unrelated illness with no evidence of disease at the
time of last follow-up. This was meticulously confirmed
by recent follow-up physician notes, radiological reports
and direct communication with family members by tele-
phone. At the time of death, they are reported to have
been disease-free for 76 months, 70 months, and 63
months, respectively.
During the follow-up period, APR was performed to
resolve anal obstruction in one patient presenting with
locoregional recurrence.
The 5-year overall, disease-free, and colostomy-free sur-
vival rates were 84.7%, 82.9% and 96.6%, respectively
(Figure 1). No significant differences in 5-year OS and
DFS rates between patients treated with CRT alone and
CRT with consolidation chemotherapy was observed (OS
88.9% in CRT alone vs. 82.6%, respectively, P = 0.465;
DFS 77.8% in CRT alone vs. 85.2%, respectively, P =
0.233). Overall treatment outcome is depicted in Figure 2.
Toxicity
Table 2 lists the toxicities occurring during the CRT and
consolidation periods.
During CRT, no grade IV toxicity was observed. However,
Grade III hematologic toxicities included neutropenia in 3
patients (9.7%), anemia in 1 (3.2%), and thrombocyto-
penia in 2 (6.5%). Febrile neutropenia occurred in 2
patients (6.5%). As expected, more than half of the
patients developed grade 3 radiation dermatitis (54.8%).
Other chemotherapy-related toxicities were mild to mod-
erate and disappeared with simple medication.
In the consolidation chemotherapy group, grade III and
IV hematologic toxicities were neutropenia in 7 patients
(33.3%), thrombocytopenia in 2 (9.5%). Febrile neutro-
penia was documented in 2 patients (9.5%) and com-
pletely recovered with supportive care. There were no
treatment-related mortalities.
Late toxicity was observed in 5 patients (16.1%). The most
common late complications were lymphedema (3
patients, 9.7%) followed by perineal fibrosis (1, 3.2%)
and deep venous thrombosis (1, 3.2%). All patients with-
out recurrence have retained normal anal function, and
no patient required a colostomy due to complications.
Discussion
ASCC is a rare malignancy, with incidences less than 1%
[29]. Therefore, the exposure of the average oncologist to
ASCC is limited, even at large cancer centers. These factors
explain, in part, the relative paucity of large, randomized
clinical trials comparing treatment modalities for anal car-
cinoma.
Since the original contribution by Nigro et al [1]. in 1974,
concomitant 5-FU and MMC therapy has been established
as the standard in several randomized trials [11-13]. These
trials have demonstrated that the inclusion of MMC
resulted in superior outcomes in terms of local control
and DFS rates. In a result from UKCCCR trial, local failure
rate at 3 years was 39% in CRT arm compared with 61%
Treatment outcomeFigure 2
Treatment outcome. Abbreviation: CR, complete 
response; PR, partial response.
The overall, disease-free, and colostomy-free survivalFigure 1
The overall, disease-free, and colostomy-free survival.Page 5 of 8
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rate was higher (80% vs. 54%) with the addition of chem-
otherapy [12]. This difference remained during follow-up,
such that the 5-year estimates of locoregional control
showed an 18% advantage for the combined group. Addi-
tionally, the colostomy-free survival rate in the combined
group was 32% higher at 5-years. In an Intergroup trial,
the addition of MMC resulted in higher CFS at 4 years
(71% vs. 59%). The DFS rate at 4 years was also higher in
the MMC arm than in the 5-FU alone arm (73% vs. 51%)
[13]. However, this regimen is associated with severe tox-
icity in 25–50% of patients and a mortality rate of 1–3%.
Additional investigation has centered on alternate regi-
mens, such as the substitution of cisplatin for MMC. The
Cancer and Leukemia Group B (CALGB) evaluated the
regimen of induction chemotherapy with 5-FU and cispl-
atin followed by CRT with 5-FU and MMC for patients
with locally advanced anal cancer [19]. An initial report of
45 patients treated with this regimen showed a 50% 48-
month CFS and DFS rate. Based on this promising data,
the Radiation Therapy Oncology Group (RTOG) 98-11
trial recently evaluated the use of a cisplatin-based regi-
men in patients with anal cancer [30]. That trial rand-
omized 682 patients to 5-FU and MMC plus radiation or
5-FU (1,000 mg/m2 per day on days 1–4, 29–32, 57–60,
and 85–88) and cisplatin (75 mg/m2 on days 1, 29, 57,
and 85) plus radiation (45–59 Gy beginning on day 57).
There was no difference for DFS between treatment arms
(HR 1.15; P = 0.33). OS was no different and the colos-
tomy rate was higher in cisplatin-treated patients (HR =
1.6; P = 0.04), indicating that cisplatin is not superior to
MMC.
Thus, this study attempts to evaluate the long-term benefit
of cisplatin as a substitute to MMC in the treatment of
locally advanced ASCC. Further, we investigate the poten-
tial advantage of consolidation chemotherapy as the
definitive non-surgical treatment for locally advanced
ASCC.
The main findings of this study indicate that CRT with 5-
FU and cisplatin, with or without consolidation chemo-
therapy, yielded marked complete tumor response, high
local control rate, and favorable long-term survival out-
come. Evaluation after CRT revealed a CR rate of 90.3%
and a PR rate of 9.7%. The final CR rate after consolida-
tion chemotherapy reached 96.8%. The 5-year OS was
also encouraging at 84.7%. These results compare favora-
bly with those obtained from CRT with 5-FU and cispla-
tin, in which reported OS ranged from 56–73% [3,4,14-
17].
Moreover, acute or late toxicities in our series seemed
more favorable than those observed with 5-FU and MMC
[11-13]. No grade IV toxicity or mortality was observed in
our study. Furthermore, the late toxicities in our patients
were much less severe than those reported from CRT with
MMC. Importantly, none of our patients required a tem-
porary or permanent colostomy for the palliation of pain
or incontinence.
We deliberately did not prescribe full dose chemotherapy
for the elderly or patients with poor performance status in
this study. This decision was supported by reported inci-
dence of severe complications experienced by these
patients undergoing combined treatment [31,32].
Table 2: Acute toxicity evaluation per patient.
Chemoradiation period (n = 31) Consolidation chemotherapy period (n = 21)
Acute Toxicity Grade (No. of patients) Incidence of ≥ Grade 3 Grade (No. of patients) Incidence of ≥ Grade 3
1 2 3 4 (%) 1 2 3 4 (%)
Hematological
Neutopenia 2 3 3 0 9.7 0 3 2 5 33.3
Anemia 5 6 1 0 3.2 2 4 0 0 0
Thrombocytopenia 0 0 2 0 6.5 0 0 0 2 9.5
Febrile neutropenia 0 0 2 0 6.5 0 0 2 0 9.5
Non-hematological
Stomatitis 1 4 0 0 0 3 4 0 0 0
Diarrhea 3 9 0 0 0 2 4 0 0 0
Constipation 1 1 0 0 0 0 0 0 0 0
Nausea/vomiting 3 16 0 0 0 3 7 0 0 0
Asthenia 0 2 0 0 0 0 2 1 0 4.8
Abdominal pain 2 4 0 0 0 0 0 0 0 0
Infection 0 2 1 0 3.2 0 0 0 0 0
Dermatitis 3 6 17 0 54.8 0 0 0 0 0Page 6 of 8
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40% of deaths from anal cancer occurred with disease
identified outside of the pelvis [11]. Therefore, in an effort
to optimize both local and distant disease with high com-
pliance, our center has continued to use consolidation
chemotherapy with complete responders. Consolidation
chemotherapy proved tolerable in our study and the
majority (90.5%) of patients who started consolidation
chemotherapy completed 4 cycles of consolidation chem-
otherapy, as scheduled. Unfortunately, we did not dem-
onstrate any differences in survival or recurrence patterns
between patients with or without consolidation chemo-
therapy. However, the sample size in our study was too
small to statistically detect significant differences. Thus, a
multi-institutional randomized trial will be required to
answer questions concerning the potential role of consol-
idation chemotherapy in ASCC. This strategy is under
evaluation in the United Kingdom, based on a similar
hypothesis that such treatment can improve both local
and distant control rates [33].
Historically, APR has been used for salvage attempts in the
majority of patients who had either gross or microscopic
residual disease following combined modality treatments
[34]. However, it appears that surgical salvage is often
ineffective in preventing subsequent local recurrence and
death from distant metastasis [34]. A trial from Intergroup
(RTOG 87-04/ECOG1289) [13] reported that 27 patients
with residual disease after CRT were successfully treated
with salvage CRT using 5-FU and cisplatin. Of 24 assessa-
ble patients, 12 attained CR and five of the 12 did not
require APR at 3 years. This study also demonstrates a pos-
sible benefit of salvage chemotherapy using 5-FU and cis-
platin in patients with residual disease following initial
CRT. In our study, additional chemotherapy was able to
salvage, without colostomy, 2 of 3 patients who failed to
attain CR after initial CRT, demonstrating the chemosen-
sitive nature of ASCC [35,36].
Conclusion
Our study shows that CRT with 5-FU and cisplatin, with
or without consolidation chemotherapy, was well toler-
ated and proved highly encouraging in terms of long-term
survival and the preservation of anal function in ASCC.
These data further support the indication to treat anal can-
cer with a combination of 5-FU and cisplatin as primary
treatment. However, the activity of this regimen needs to
be tested in phase III randomized trials before it can be
implemented in standard clinical practice. The second UK
phase III anal cancer trial (ACT II) are currently in progress
for that purpose [37].
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